Cargando…

Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AML

SIMPLE SUMMARY: Children with acute myeloid leukemia (AML) experience unacceptably poor survival outcomes and are at high risk of relapse. Current treatment options are limited, and standard strategies rely on intensive chemotherapy to achieve remission, frequently resulting in treatment-related mor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strachan, Debbie C., Gu, Christine J., Kita, Ryosuke, Anderson, Erica K., Richardson, Michelle A., Yam, George, Pimm, Graham, Roselli, Jordan, Schweickert, Alyssa, Terrell, Maci, Rashid, Raushan, Gonzalez, Alan K., Oviedo, Hailey H., Alozie, Michelle C., Ilangovan, Tamilini, Marcogliese, Andrea N., Tada, Hiroomi, Santaguida, Marianne T., Stevens, Alexandra M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777060/ https://www.ncbi.nlm.nih.gov/pubmed/36551725 http://dx.doi.org/10.3390/cancers14246240

Ejemplares similares

Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated
por: Stevens, Alexandra McLean, et al.
Publicado: (2023)

Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay
por: Stieglitz, Elliot, et al.
Publicado: (2023)

Enhancer polymorphisms at the IKZF1 susceptibility locus for acute lymphoblastic leukemia impact B-cell proliferation and differentiation in both Down syndrome and non-Down syndrome genetic backgrounds
por: Gant, Vincent U., et al.
Publicado: (2021)

Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency
por: Perez, Monika W., et al.
Publicado: (2021)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

The Challenge of AML in Older Patients
por: Burnett, Alan K
Publicado: (2013)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

Combination Therapies Targeting Apoptosis in Paediatric AML: Understanding the Molecular Mechanisms of AML Treatments Using Phosphoproteomics
por: Ali, Ahlam A., et al.
Publicado: (2023)

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

Maintenance therapy for AML after allogeneic HCT
por: Nayak, Rahul K., et al.
Publicado: (2022)

CALCRL Gene is a Suitable Prognostic Factor in AML/ETO(+) AML Patients
por: Wang, Rongrong, et al.
Publicado: (2022)

Phospholipid metabolism regulates AML growth and stemness
por: Xu, Mingjing, et al.
Publicado: (2019)

MicroRNA–mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients
por: Bhise, Neha S., et al.
Publicado: (2016)

Investigation of distinct gene expression profile patterns that can improve the classification of intermediate-risk prognosis in AML patients
por: Eshibona, Nasr, et al.
Publicado: (2023)

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017)

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
por: Othman, Jad, et al.
Publicado: (2023)

Emerging CAR T Cell Strategies for the Treatment of AML
por: Vishwasrao, Paresh, et al.
Publicado: (2022)

Targeting glutamine uptake in AML
por: Jacque, Nathalie, et al.
Publicado: (2014)

AML treatment in older adults
por: Sehgal, Alison, et al.
Publicado: (2015)

Impact of CNA on AML prognosis
por: Gonzales, Fanny, et al.
Publicado: (2017)

Treatments for children and adolescents with AML
por: Kim, Hyery
Publicado: (2020)

Emerging agents and regimens for AML
por: Liu, Hongtao
Publicado: (2021)

Von AML bis Zytokinfreisetzung
por: Klein, Friederike
Publicado: (2022)

Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018)

Drug resistant epilepsy with mesial temporal sclerosis as possible late neurological complication in two AML survivors after stem cell transplantation
por: Yam, Kwan-Ming Karen, et al.
Publicado: (2018)

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation
por: Federzoni, Elena A., et al.
Publicado: (2014)

De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes
por: Lopes, Matheus Rodrigues, et al.
Publicado: (2017)

Oncogenic Roles Of A Histone Methyltransferase SETDB2 In AML1-ETO Positive AML
por: Mu, Guangfu, et al.
Publicado: (2020)

IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells
por: Liss, Franziska, et al.
Publicado: (2021)

Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy
por: Uy, Geoffrey L., et al.
Publicado: (2016)

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)
por: Jacoby, Meagan A., et al.
Publicado: (2021)

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
por: Fuhrmann, Irene, et al.
Publicado: (2022)

Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML
por: Stockard, Bradley, et al.
Publicado: (2021)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004
por: Rasche, M, et al.
Publicado: (2017)

Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells
por: Trombly, Daniel J, et al.
Publicado: (2015)

Global Proteomic Profiling of Pediatric AML: A Pilot Study
por: Nguyen, Nam H. K., et al.
Publicado: (2021)

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
por: Freeman, Sylvie D., et al.
Publicado: (2023)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
por: Huber, Sandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pgjqv7952nns74erlhm7q4333v